evidence table
Ginkgo Cognition Randomized Trial Evidence Table
Structured evidence table for Ginkgo Cognition Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Ginkgo Cognition Randomized Trial | In addition, an overview of systematic reviews synthesized the broader EGb 761 evidence base across indications and highlighted that conclusions require caution given the methodological limitations of many reviews []. | 3 | Yang YoungSoon (2026) | Ginkgo Biloba for Alzheimer’s Disease: From Mixed Dementia Trials to Biomarker-Confirmed Mild Cognitive Impairment—What Have We Learned over Two Decades, and Is There Finally a Bit of Hope? |
| Ginkgo Cognition Randomized Trial | Real-world observational analyses have also reported associations between prescriptions of Ginkgo leaf extract and reduced risk of dementia severity progression, albeit with the inherent limitations of non-randomized designs []. | 3 | Yang YoungSoon (2026) | Ginkgo Biloba for Alzheimer’s Disease: From Mixed Dementia Trials to Biomarker-Confirmed Mild Cognitive Impairment—What Have We Learned over Two Decades, and Is There Finally a Bit of Hope? |
| Ginkgo Cognition Randomized Trial | Accordingly, this review revisits the historical evidence base with explicit attention to heterogeneity and methodological design, and then examines biomarker-confirmed AD-spectrum studies as a potential pivot point. | 3 | Yang YoungSoon (2026) | Ginkgo Biloba for Alzheimer’s Disease: From Mixed Dementia Trials to Biomarker-Confirmed Mild Cognitive Impairment—What Have We Learned over Two Decades, and Is There Finally a Bit of Hope? |
| Ginkgo Cognition Randomized Trial | 1 2 Alzheimer’s disease (AD) remains the most common cause of dementia and continues to impose a major burden on patients, caregivers, and healthcare systems []. | 3 | Yang YoungSoon (2026) | Ginkgo Biloba for Alzheimer’s Disease: From Mixed Dementia Trials to Biomarker-Confirmed Mild Cognitive Impairment—What Have We Learned over Two Decades, and Is There Finally a Bit of Hope? |
| Ginkgo Cognition Randomized Trial | These limitations have catalyzed an increased global focus on nutraceuticals and phytomedicines possessing multimodal biological activities that transcend mere monoamine reuptake inhibition. | 3 | Li Xikun (2026) | Rhodiola rosea , Ginkgo biloba , and Ashwagandha as novel antidepressant supplements: converging monoaminergic, neurotrophic, anti-inflammatory, and brain health pathways in depressive disorders |
| Ginkgo Cognition Randomized Trial | Unlike prior reviews that focus on individual herbs or broadly defined adaptogens, the present review integrates mechanistic, preclinical, and clinical evidence across these three agents to highlight their complementary rather than redundant actions. | 3 | Li Xikun (2026) | Rhodiola rosea , Ginkgo biloba , and Ashwagandha as novel antidepressant supplements: converging monoaminergic, neurotrophic, anti-inflammatory, and brain health pathways in depressive disorders |
| Ginkgo Cognition Randomized Trial | Rhodiola rosea Ginkgo biloba Withania somnifera A comprehensive and structured literature search was conducted to identify preclinical, translational, and clinical evidence related to the antidepressant effects and underlying neurobiological mechanisms of,, and(Ashwagandha). | 3 | Li Xikun (2026) | Rhodiola rosea , Ginkgo biloba , and Ashwagandha as novel antidepressant supplements: converging monoaminergic, neurotrophic, anti-inflammatory, and brain health pathways in depressive disorders |
| Ginkgo Cognition Randomized Trial | 1 2 3 Rhodiola rosea Ginkgo biloba Withania somnifera Depression constitutes one of the most incapacitating neuropsychiatric disorders globally (). | 3 | Li Xikun (2026) | Rhodiola rosea , Ginkgo biloba , and Ashwagandha as novel antidepressant supplements: converging monoaminergic, neurotrophic, anti-inflammatory, and brain health pathways in depressive disorders |
Source documents
- Ginkgo Biloba for Alzheimer’s Disease: From Mixed Dementia Trials to Biomarker-Confirmed Mild Cognitive Impairment—What Have We Learned over Two Decades, and Is There Finally a Bit of Hope?
- Rhodiola rosea , Ginkgo biloba , and Ashwagandha as novel antidepressant supplements: converging monoaminergic, neurotrophic, anti-inflammatory, and brain health pathways in depressive disorders